Samsung Bioepis acquires product approval of ‘Samfenet,’ Herceptin biosimilar
‘SB3(product name: Samfenet, generic name: trastuzumab),’ a Samsung Bioepis’ cancer therapy biosimilar, acquire product approval from the Ministry of Food and Drug Safety on the 8th.
Samfenet is a biosimilar of ‘Herceptin(trastuzumab),’ a antibody for various cancers, such as metastatic breast c...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
